BNB Plus Corp

BNBX

Market cap $5.63M

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has successfully manufactured and shipped the largest single LineaDNA order in Company history, valued at over $390,000 USD. The approximately 5-gram shipment, manufactured by the Company's LineaRx, Inc. subsidiary, was delivered under the Company's previously announced supply agreement for the bulk manufacture of LineaDNA used as a functional component of a cancer diagnostic test (“the “.

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today provided a corporate update highlighting its recent strategic treasury growth, expected significant narrowing of losses at its LineaRx, Inc. (“LineaRx”) subsidiary, and the launch of a new corporate website and branding. Significant Addition to BNB Treasury The Company has opportunistically deployed an additional approximately $3 million to acquire additional BNB tokens at an average price of approximately.

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: BNBX) (the “Company”) today announced that it will change its name to BNB Plus Corp. (“BNB Plus”), reflecting the Company's commitment to delivering a yield-optimized, BNB-based digital asset treasury strategy leveraging the Binance ecosystem. Alongside the rebrand, the Company also announced the appointment of Josh Kruger as Chairman of the Board. Mr. Kruger has deep expertise in managing blockchain-native assets for yield.

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: BNBX) ( “BNBX” or the “Company”) today announced the launch of BNBX.io, which provides real-time portfolio metrics updating the market on the Company's BNB treasury holdings, key valuation metrics, and detailed information about the capitalization structure of the Company (the “Dashboard”). “The launch of our Dashboard reflects BNBX's commitment to real-time transparency and clear investor communication,” said Patrick Horsm.

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: BNBX) (“Applied DNA”, “BNBX” or the “Company”), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid production solutions, today announced the successful close of its previously announced private investment in public equity (“PIPE”) financing led by institutional DeFi and TradFi investors. The PIPE resulted in gross proceeds of approximately $27 Million to th.

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid production solutions, today announced that it will change its ticker symbol on the Nasdaq Capital Market (“Nasdaq”) from “APDN” to “BNBX”, effective at the opening of trading on Tuesday October 7, 2025. The ticker BNBX underscores the Company's strategic commitment to.

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a biotechnology company focused on providing nucleic acid production solutions, today announced up to $58 million in commitments for a private investment in public equity (“PIPE”) offering led by institutional investors to initiate a digital asset treasury strategy based on BNB, the native cryptocurrency of the Binance blockchain ecosystem, the world's largest cryptocurrency exchange1.

STONY BROOK, NY / ACCESS Newswire / September 23, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, announced that members of its business development and technical teams will be in attendance at upcoming industry conferences and present posters that underscore the Company's flexible nucleic acid production solutions designed to meet critical unmet needs for the manufacture of advanced biotherapeutics: 4th Annual mRNA Process Development and CMC Summit (Boston, September 23-25) Title: Fast-tracking mRNA Medicines: a synthetic DNA platform to optimize mRNA production Authors: Atsuko Sangria1, Aaron Chung2, and Yuhua Sun2 Poster session date/time: Wednesday, September 24, at 3:10 p.m. Eastern Poster: link Also at the mRNA conference, Applied DNA will feature its IVT Discovery Kit, a powerful platform for evaluating and optimizing in vitro transcription (IVT).

STONY BROOK, NY / ACCESS Newswire / August 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, today reported financial results for its third quarter of fiscal 2025 ended June 30, 2025. The Company's Form 10-Q for its fiscal third quarter can be viewed on the SEC Filings page of its Investor Relations website.

STONY BROOK, NY / ACCESS Newswire / July 24, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in synthetic DNA manufacturing powered by scalable PCR platforms, today announced it received a seventh follow-on order valued at more than $600,000 for a multi-gram quantity of LineaDNA™. The follow-on order was placed by a global manufacturer of in vitro diagnostics (IVDs) under a long-standing supply agreement for the bulk manufacture of LineaDNA used as a functional component of a cancer diagnostic test.